Enhancement of Liver and Pancreas on Late Hepatic Arterial Phase Imaging: Quantitative Comparison Among Multiple Gadolinium-Based Contrast Agents at 1.5 Tesla MRI

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

To compare enhancement of the liver and pancreas quantitatively on late hepatic arterial phase images among various gadolinium-based contrast agents (GBCAs) at 1.5 Tesla (T) MRI.

Materials and Methods

Patients underwent consecutive MR studies with the following GBCAs: gadopentetate dimeglumine (0.1 mmol/kg) gadobenate dimeglumine (0.05 mmol/kg), gadoxetic acid, and gadobutrol group. The enhancement of liver and pancreas was evaluated quantitatively on late hepatic arterial phase. Relative pancreas-to-liver enhancement ratio was also calculated.

Results

Mean % enhancement of the liver and the pancreas was 21.57 and 55.40, and mean relative pancreas to liver enhancement was 2.23. Mean % enhancement of the liver for gadopentetate, gadobenate, gadoxetic, and gadobutrol were 20.4 ± 12.3, 21.7 ± 7.1, 16.2 ± 6.1, 29.1 ± 21.9. Significant difference was observed for % enhancement of liver comparing gadobutrol and gadoxetic (P = 0.048). Mean % enhancement of pancreas for gadopentetate, gadobenate, gadoxetic, and gadobutrol were 53.6 ± 12.6, 60.1 ± 13.7, 52.7 ± 10.6, 54.7 ± 19.5. No significant differences were observed for % enhancement of pancreas (P > 0.05). No significant differences were observed for relative pancreas-to-liver enhancement ratio (P > 0.05).

Conclusion

Our study describes % enhancement of liver and pancreas using various GBCAs. The data may provide reference material on relaxation properties of GBCAs in vivo. J. Magn. Reson. Imaging 2013;38:102–108. © 2013 Wiley Periodicals, Inc.

Related Topics

    loading  Loading Related Articles